An update on the use of immunoglobulins as treatment for myasthenia gravis

References

• Gilhus NE, Skeie GO, Romi F, et al. Myasthenia gravis - autoantibody characteristics and their implications for therapy. Nat Rev Neurol. 2016;12(5):259–268.
   PubMed Web of Science ®Google Scholar
• Marx A, Pfister F, Schalke B, et al. The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmun Rev. 2013;12(9):875–884.
   PubMed Web of Science ®Google Scholar
• Wolfe GI, Kaminski HJ, Aban IB, et al., Randomized trial of thymectomy in myasthenia gravis. N Engl J Med. 2016;375(6):511–522.
   PubMed Web of Science ®Google Scholar
• Menon D, Katzberg H, Barnett C, et al. Thymoma pathology and myasthenia gravis outcomes. Muscle Nerve. 2021;63(6):868–873.
   PubMedGoogle Scholar
• Narayanaswami P, Sanders DB, Wolfe G, et al., International consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 2021;96(3):114–122.
   PubMed Web of Science ®Google Scholar
• Ebadi H, Barth D, Bril V. Safety of plasma exchange therapy in patients with myasthenia gravis. Muscle Nerve. 2013;47(4):510–514.
   PubMed Web of Science ®Google Scholar
• Barth D, Nabavi Nouri M, Ng E, et al. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology. 2011;76(23):2017–2023.
   PubMed Web of Science ®Google Scholar
• Jensen P, Bril V. A comparison of the effectiveness of intravenous immunoglobulin and plasma exchange as preoperative therapy of myasthenia gravis. J Clin Neuromuscul Dis. 2008;9(3):352–355.
   PubMedGoogle Scholar
• Alcantara M, Sarpong E, Barnett C, et al. Chronic immunoglobulin maintenance therapy in myasthenia gravis. Eur J Neurol. 2021;28(2):639–646.
   PubMed Web of Science ®Google Scholar
• Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol. 2013;13(3):176–189.
   PubMed Web of Science ®Google Scholar
• Fehr J, Hofmann V, Rappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N Engl J Med. 1982;306(21):1254–1258.
   PubMed Web of Science ®Google Scholar
• Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 2001;291(5503):484–486.
   PubMed Web of Science ®Google Scholar
• Lünemann JD, Nimmerjahn F, Dalakas MC. Intravenous immunoglobulin in neurology–mode of action and clinical efficacy. Nat Rev Neurol. 2015;11(2):80–89.
   PubMed Web of Science ®Google Scholar
• Barnett C, Herbelin L, Dimachkie MM, et al. Measuring clinical treatment response in myasthenia gravis. Neurol Clin. 2018;36(2):339–353.
   PubMedGoogle Scholar
• Jaretzki A, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. task force of the medical scientific advisory board of the myasthenia gravis foundation of America. Ann Thorac Surg. 2000;70(1):327–334.
   PubMed Web of Science ®Google Scholar
• Hellmann MA, Mosberg-Galili R, Lotan I, et al. Maintenance IVIg therapy in myasthenia gravis does not affect disease activity. J Neurol Sci. 2014;338(1–2):39–42.
   PubMed Web of Science ®Google Scholar
• Wilf-Yarkoni A, Lotan I, Steiner I, et al. Chronic low-dose intravenous immunoglobulins as steroid-sparing therapy in myasthenia gravis. J Neurol. 2021;268(10):3871–3877.
   PubMedGoogle Scholar
• Gajdos P, Outin H, Elkharrat D, et al. High-dose intravenous gammaglobulin for myasthenia gravis. Lancet. 1984;1(8373):406–407.
   PubMed Web of Science ®Google Scholar
• Ippoliti G, Cosi V, Piccolo G, et al. High-dose intravenous gammaglobulin for myasthenia gravis. Lancet. 1984;324(8406):809–810.
   Google Scholar
• Gajdos P, Simon N, de Rohan-Chabot P, et al. Long-term effects of plasma exchange in myasthenia. results of a randomized study. Presse Med. 1983;12(15):939–942.
   PubMedGoogle Scholar
• Gajdos P, Outin HD, Morel E, et al. High-Dose intravenous gamma globulin for myasthenia gravis: an alternative to plasma exchange? Ann N Y Acad Sci. 1987;505(1):842–844.
   Google Scholar
• Gajdos P, Chevret S, Clair B, et al. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. myasthenia gravis clinical study group. Ann Neurol. 1997;41(6):789–796.
   PubMed Web of Science ®Google Scholar
• Gajdos P, Tranchant C, Clair B, et al., Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial. Arch Neurol. 2005;62(11):1689–1693.
   PubMedGoogle Scholar
• Barohn RJ, McIntire D, Herbelin L, et al. Reliability testing of the quantitative myasthenia gravis score. Ann N Y Acad Sci. 1998;841(1 MYASTHENIA GR):327–334.
   Google Scholar
• Katzberg HD, Barnett C, Merkies ISJ, et al. Minimal clinically important difference in myasthenia gravis: outcomes from a randomized trial. Muscle Nerve. 2014;49(5):406–407.
   Google Scholar
• Eienbröker C, Seitz F, Spengler A, et al., Intravenous immunoglobulin maintenance treatment in myasthenia gravis: a randomized, controlled trial sample size simulation. Muscle Nerve. 2014;50(6): 999–1004.
   PubMedGoogle Scholar
• Wolfe GI, Barohn RJ, Foster BM, et al. Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis. Muscle Nerve. 2002;26(4):549–552.
   PubMed Web of Science ®Google Scholar
• Wolfe GI, Herbelin L, Nations SP, et al. Myasthenia gravis activities of daily living profile. Neurology. 1999;52(7):1487.
   PubMed Web of Science ®Google Scholar
• Burns TM, Conaway M, Sanders DB; Group MCaM-QS. The MG Composite: a valid and reliable outcome measure for myasthenia gravis. Neurology. 2010;74(18):1434–1440.
   PubMed Web of Science ®Google Scholar
• Raggi A, Antozzi C, Baggi F, et al. Validity, reliability, and sensitivity to change of the myasthenia gravis activities of daily living profile in a sample of Italian myasthenic patients. Neurol Sci. 2017;38(11):1927–1931.
   PubMedGoogle Scholar
• Muppidi S, Wolfe GI, Conaway M, et al., GROUP MCAM-QS. MG-ADL: still a relevant outcome measure. Muscle Nerve. 2011;44(5):727–731.
   PubMedGoogle Scholar
• Wolfe GI, Barohn RJ, Sanders DB, et al. Comparison of outcome measures from a trial of mycophenolate mofetil in myasthenia gravis. Muscle Nerve. 2008;38(5):1429–1433.
   PubMed Web of Science ®Google Scholar
• Benatar M, Sanders DB, Burns TM, et al., Recommendations for myasthenia gravis clinical trials. Muscle Nerve. 2012;45(6): 909–917.
   PubMed Web of Science ®Google Scholar
• Barnett C, Bril V, Kapral M, et al. Development and validation of the myasthenia gravis impairment index. Neurology. 2016;87(9):879–886.
   PubMedGoogle Scholar
• Barnett C, Bril V, Kapral M, et al. Myasthenia gravis impairment index: responsiveness, meaningful change, and relative efficiency. Neurology. 2017;89(23):2357–2364.
   PubMed Web of Science ®Google Scholar
• clinicaltrials.gov/ct2/NCT04728425. [cited 2020 Jan 02]. https://clinicaltrials.gov/ct2/show/NCT04728425
   Google Scholar
• Burns TM. The MG composite: an outcome measure for myasthenia gravis for use in clinical trials and everyday practice. Ann N Y Acad Sci. 2012;1274(1):99–106.
   PubMedGoogle Scholar
• Burns TM, Sadjadi R, Utsugisawa K, et al., International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r. Muscle Nerve. 2016;54(6): 1015–1022.
   PubMed Web of Science ®Google Scholar
• Fateh-Moghadam A, Wick M, Besinger U, et al. High-dose intravenous gammaglobulin for myasthenia gravis. Lancet. 1984;323(8381):848–849.
   Google Scholar
• Arsura E. Experience with intravenous immunoglobulin in myasthenia gravis. Clin Immunol Immunopathol. 1989;53(2 Pt 2):S170–9.
   PubMedGoogle Scholar
• Arsura EL, Bick A, Brunner NG, et al. Effects of repeated doses of intravenous immunoglobulin in myasthenia gravis. Am J Med Sci. 1988;295(5):438–443.
   PubMedGoogle Scholar
• Rønager J, Ravnborg M, Hermansen I, et al. Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis. Artif Organs. 2001;25(12):967–973.
   PubMed Web of Science ®Google Scholar
• Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology. 2007;68(11):837–841.
   PubMed Web of Science ®Google Scholar
• Karelis G, Balasa R, De Bleecker JL, et al. A phase 3 multicenter, prospective, open-label efficacy and safety study of immune globulin [human] 10% caprylate/chromatography purified in patients with myasthenia gravis exacerbations. Eur Neurol. 2019;81(5–6):223–230.
   PubMed Web of Science ®Google Scholar
• A pilot trial to assess the feasibility and efficacy of SCIG in patients with MG exacerbation [SCIG-MG] [Internet]. 2016. Available from: ClinicalTrials.gov Identifier: NCT02774239.
   Google Scholar
• Beecher G, Anderson D, Siddiqi ZA. Subcutaneous immunoglobulin in myasthenia gravis exacerbation: a prospective, open-label trial. Neurology. 2017;89(11):1135–1141.
   PubMedGoogle Scholar
• Dimachkie M, Bril V, Levine T, et al. Subcutaneous immunoglobulin in myasthenia gravis: results of a north american open label study. Neurology. 2019;92(15 Supplement):N4.002.
   Google Scholar
• Putko BN, Beecher G, Siddiqi ZA. pharmacodynamic properties of subcutaneous immunoglobulin in myasthenia gravis: sub-analyses from an open-label trial. Front Neurol. 2020;11:921.
   PubMedGoogle Scholar
• Menon D, Barnett C, Bril V. Novel treatments in myasthenia gravis. Front Neurol. 2020;11:538.
   PubMed Web of Science ®Google Scholar
• Achiron A, Barak Y, Miron S, et al. Immunoglobulin treatment in refractory Myasthenia gravis. Muscle Nerve. 2000;23(4):551–555.
   PubMedGoogle Scholar
• Hilkevich O, Drory VE, Chapman J, et al. The use of intravenous immunoglobulin as maintenance therapy in myasthenia gravis. Clin Neuropharmacol. 2001;24(3):173–176.
   PubMedGoogle Scholar
• Sorgun MH, Sener HO, Yucesan C, et al. Intravenous immunoglobulin for prophylaxis of acute exacerbation in Myasthenia Gravis. Neurol Sci. 2014;35(6):891–896.
   PubMed Web of Science ®Google Scholar
• Waheed W, Ayer GA, Jadoo CL, et al. Safety of intravenous immune globulin in an outpatient setting for patients with neuromuscular disease. Muscle Nerve. 2019;60(5):528–537.
   PubMedGoogle Scholar
• Bourque PR, Pringle CE, Cameron W, et al. Subcutaneous immunoglobulin therapy in the chronic management of myasthenia gravis: a retrospective cohort study. PLoS One. 2016;11(8):e0159993.
   PubMedGoogle Scholar
• Kovács E, Dankó K, Nagy-Vince M, et al. Long-term treatment of refractory myasthenia gravis with subcutaneous immunoglobulin. Ther Adv Neurol Disord. 2017;10(11):363–366.
   PubMedGoogle Scholar
• Yoon MS, Gold R, Kerasnoudis A. Subcutaneous immunoglobulin in treating inflammatory neuromuscular disorders. Ther Adv Neurol Disord. 2015;8(4):153–159.
   PubMed Web of Science ®Google Scholar
• Pérez Nellar J, Domínguez AM, Llorens-Figueroa JA, et al. A comparative study of intravenous immunoglobulin and plasmapheresis preoperatively in myasthenia. Rev Neurol. 2001;33(5):413–416.
   PubMedGoogle Scholar
• Huang CS, Hsu HS, Kao KP, et al. Intravenous immunoglobulin in the preparation of thymectomy for myasthenia gravis. Acta Neurol Scand. 2003;108(2):136–138.
   PubMedGoogle Scholar
• Alipour-Faz A, Shojaei M, Peyvandi H, et al. A comparison between IVIG and plasma exchange as preparations before thymectomy in myasthenia gravis patients. Acta Neurol Belg. 2017;117(1):245–249.
   PubMedGoogle Scholar
• Gamez J, Salvadó M, Carmona F, et al. Intravenous immunoglobulin to prevent myasthenic crisis after thymectomy and other procedures can be omitted in patients with well-controlled myasthenia gravis. Ther Adv Neurol Disord. 2019;12:1756286419864497.
   Google Scholar
• Guptill JT, Sanders DB, Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve. 2011;44(1):36–40.
   PubMed Web of Science ®Google Scholar
• Pasnoor M, Wolfe GI, Nations S, et al. Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience. Muscle Nerve. 2010;41(3):370–374.
   PubMedGoogle Scholar
• Takahashi H, Kawaguchi N, Nemoto Y, et al. High-dose intravenous immunoglobulin for the treatment of MuSK antibody-positive seronegative myasthenia gravis. J Neurol Sci. 2006;247(2):239–241.
   PubMedGoogle Scholar
• Shibata-Hamaguchi A, Samuraki M, Furui E, et al., Long-term effect of intravenous immunoglobulin on anti-MuSK antibody-positive myasthenia gravis. Acta Neurol Scand. 2007;116(6): 406–408.
   PubMedGoogle Scholar
• Grover KM, Sripathi N. Myasthenia gravis and pregnancy. Muscle Nerve. 2020;62(6):664–672.
   PubMed Web of Science ®Google Scholar
• Alharbi M, Menon D, Barnett C, et al. Myasthenia gravis and pregnancy: toronto specialty center experience. Can J Neurol Sci. 2021;48(6):767–771.
   PubMedGoogle Scholar
• Banner HN, Niles KM, Ryu M, et al. Myasthenia Gravis in pregnancy: systematic review and case series. Obstet Med. 2022;1753495X2110418.
   Google Scholar
• Gamez J, Salvado M, Casellas M, et al. Intravenous immunoglobulin as monotherapy for myasthenia gravis during pregnancy. J Neurol Sci. 2017;383:118–122.
   PubMedGoogle Scholar
• Horiuchi KS, Sato C, Odo T. Successful early treatment with intravenous immunoglobulin for seronegative myasthenia gravis with onset during pregnancy: a case report. Neurol Clin Neurosci. 2016;4(6):228–229.
   Google Scholar
• Santos E, Braga A, Gabriel D, et al. MuSK myasthenia gravis and pregnancy. Neuromuscul Disord. 2018;28(2):150–153.
   PubMed Web of Science ®Google Scholar
• Neves AR, Monteiro P, Matos A, et al. Anti-MuSK-positive myasthenia gravis diagnosed during pregnancy: new challenges for an old disease? BMJ Case Rep. 2015;2015(jan05 1):bcr2014207708–bcr2014207708.
   PubMedGoogle Scholar
• Gilhus NE. Myasthenia gravis can have consequences for pregnancy and the developing child. Front Neurol. 2020;11:554.
   PubMedGoogle Scholar
• Selcen D, Dabrowski ER, Michon AM, et al. High-dose intravenous immunoglobulin therapy in juvenile myasthenia gravis. Pediatr Neurol. 2000;22(1):40–43.
   PubMedGoogle Scholar
• Liew WK, Powell CA, Sloan SR, et al. Comparison of plasmapheresis and intravenous immunoglobulin as maintenance therapies for juvenile myasthenia gravis. JAMA Neurol. 2014;71(5):575–580.
   PubMed Web of Science ®Google Scholar
• Jastrzębska A, Jastrzębski M, Ryniewicz B, et al. Treatment outcome in juvenile-onset myasthenia gravis. Muscle Nerve. 2019;59(5):549–554.
   PubMedGoogle Scholar
• Barraud C, Desguerre I, Barnerias C, et al. Clinical features and evolution of juvenile myasthenia gravis in a French cohort. Muscle Nerve. 2018;57(4):603–609.
   PubMedGoogle Scholar
• Díez-Porras L, Homedes C, Alberti MA, et al. Intravenous immunoglobulins may prevent prednisone-exacerbation in myasthenia gravis. Sci Rep. 2020;10(1):13497.
   PubMedGoogle Scholar